Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.46
RHHBY's Cash to Debt is ranked lower than
86% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. RHHBY: 0.46 )
Ranked among companies with meaningful Cash to Debt only.
RHHBY' s 10-Year Cash to Debt Range
Min: 0.36  Med: 1.43 Max: N/A
Current: 0.46
Equity to Asset 0.26
RHHBY's Equity to Asset is ranked lower than
86% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RHHBY: 0.26 )
Ranked among companies with meaningful Equity to Asset only.
RHHBY' s 10-Year Equity to Asset Range
Min: 0.1  Med: 0.39 Max: 0.59
Current: 0.26
0.1
0.59
F-Score: 5
Z-Score: 3.72
M-Score: -2.80
WACC vs ROIC
8.51%
32.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 27.04
RHHBY's Operating margin (%) is ranked higher than
90% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. RHHBY: 27.04 )
Ranked among companies with meaningful Operating margin (%) only.
RHHBY' s 10-Year Operating margin (%) Range
Min: 4.53  Med: 24.87 Max: 35.01
Current: 27.04
4.53
35.01
Net-margin (%) 17.74
RHHBY's Net-margin (%) is ranked higher than
86% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. RHHBY: 17.74 )
Ranked among companies with meaningful Net-margin (%) only.
RHHBY' s 10-Year Net-margin (%) Range
Min: -13.67  Med: 18.74 Max: 30.16
Current: 17.74
-13.67
30.16
ROE (%) 49.64
RHHBY's ROE (%) is ranked higher than
97% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. RHHBY: 49.64 )
Ranked among companies with meaningful ROE (%) only.
RHHBY' s 10-Year ROE (%) Range
Min: -16.17  Med: 24.67 Max: 102.95
Current: 49.64
-16.17
102.95
ROA (%) 13.01
RHHBY's ROA (%) is ranked higher than
91% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. RHHBY: 13.01 )
Ranked among companies with meaningful ROA (%) only.
RHHBY' s 10-Year ROA (%) Range
Min: -5.78  Med: 11.80 Max: 17.58
Current: 13.01
-5.78
17.58
ROC (Joel Greenblatt) (%) 68.27
RHHBY's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. RHHBY: 68.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RHHBY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.9  Med: 60.85 Max: 84.52
Current: 68.27
6.9
84.52
Revenue Growth (3Y)(%) 5.00
RHHBY's Revenue Growth (3Y)(%) is ranked higher than
56% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. RHHBY: 5.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RHHBY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.3  Med: 6.00 Max: 391.7
Current: 5
-2.3
391.7
EBITDA Growth (3Y)(%) 3.10
RHHBY's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. RHHBY: 3.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RHHBY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -5.1  Med: 21.85 Max: 280
Current: 3.1
-5.1
280
EPS Growth (3Y)(%) -0.50
RHHBY's EPS Growth (3Y)(%) is ranked higher than
57% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. RHHBY: -0.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RHHBY' s 10-Year EPS Growth (3Y)(%) Range
Min: -3.8  Med: 7.70 Max: 341.1
Current: -0.5
-3.8
341.1
» RHHBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

RHHBY Guru Trades in Q3 2014

Bill Frels 2,391,096 sh (+9.44%)
Ken Fisher 1,891,406 sh (+4.30%)
» More
Q4 2014

RHHBY Guru Trades in Q4 2014

Ken Fisher 2,823,025 sh (+49.26%)
Bill Frels 2,609,371 sh (+9.13%)
» More
Q1 2015

RHHBY Guru Trades in Q1 2015

Bill Frels 2,703,876 sh (+3.62%)
Ken Fisher 2,788,126 sh (-1.24%)
» More
Q2 2015

RHHBY Guru Trades in Q2 2015

Ken Fisher 14,211,412 sh (+409.71%)
Bill Frels 2,712,376 sh (+0.31%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.03
RHHBY's P/E(ttm) is ranked higher than
67% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 36.10 vs. RHHBY: 24.03 )
Ranked among companies with meaningful P/E(ttm) only.
RHHBY' s 10-Year P/E(ttm) Range
Min: 13.05  Med: 19.55 Max: 36.39
Current: 24.03
13.05
36.39
Forward P/E 2.11
RHHBY's Forward P/E is ranked higher than
71% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 22.73 vs. RHHBY: 2.11 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.70
RHHBY's PE(NRI) is ranked higher than
66% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 35.00 vs. RHHBY: 23.70 )
Ranked among companies with meaningful PE(NRI) only.
RHHBY' s 10-Year PE(NRI) Range
Min: 13.05  Med: 19.76 Max: 44.62
Current: 23.7
13.05
44.62
P/B 12.92
RHHBY's P/B is ranked lower than
85% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. RHHBY: 12.92 )
Ranked among companies with meaningful P/B only.
RHHBY' s 10-Year P/B Range
Min: 2.64  Med: 11.20 Max: 22.21
Current: 12.92
2.64
22.21
P/S 4.49
RHHBY's P/S is ranked higher than
74% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. RHHBY: 4.49 )
Ranked among companies with meaningful P/S only.
RHHBY' s 10-Year P/S Range
Min: 2.38  Med: 4.12 Max: 6.45
Current: 4.49
2.38
6.45
PFCF 17.78
RHHBY's PFCF is ranked higher than
79% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 39.55 vs. RHHBY: 17.78 )
Ranked among companies with meaningful PFCF only.
RHHBY' s 10-Year PFCF Range
Min: 8.6  Med: 17.37 Max: 39.65
Current: 17.78
8.6
39.65
POCF 14.07
RHHBY's POCF is ranked higher than
80% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. RHHBY: 14.07 )
Ranked among companies with meaningful POCF only.
RHHBY' s 10-Year POCF Range
Min: 6.98  Med: 13.87 Max: 25.96
Current: 14.07
6.98
25.96
EV-to-EBIT 17.21
RHHBY's EV-to-EBIT is ranked higher than
70% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 27.86 vs. RHHBY: 17.21 )
Ranked among companies with meaningful EV-to-EBIT only.
RHHBY' s 10-Year EV-to-EBIT Range
Min: 7.9  Med: 14.10 Max: 32
Current: 17.21
7.9
32
PEG 6.41
RHHBY's PEG is ranked lower than
74% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 2.26 vs. RHHBY: 6.41 )
Ranked among companies with meaningful PEG only.
RHHBY' s 10-Year PEG Range
Min: 0.3  Med: 0.62 Max: 7.66
Current: 6.41
0.3
7.66
Shiller P/E 23.22
RHHBY's Shiller P/E is ranked higher than
81% of the 113 Companies
in the Global Biotechnology industry.

( Industry Median: 44.53 vs. RHHBY: 23.22 )
Ranked among companies with meaningful Shiller P/E only.
RHHBY' s 10-Year Shiller P/E Range
Min: 13.36  Med: 22.86 Max: 110.34
Current: 23.22
13.36
110.34
Current Ratio 1.35
RHHBY's Current Ratio is ranked lower than
82% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. RHHBY: 1.35 )
Ranked among companies with meaningful Current Ratio only.
RHHBY' s 10-Year Current Ratio Range
Min: 1.35  Med: 2.40 Max: 3.75
Current: 1.35
1.35
3.75
Quick Ratio 1.01
RHHBY's Quick Ratio is ranked lower than
83% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. RHHBY: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
RHHBY' s 10-Year Quick Ratio Range
Min: 1.01  Med: 2.01 Max: 3.22
Current: 1.01
1.01
3.22
Days Inventory 183.21
RHHBY's Days Inventory is ranked lower than
69% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 120.98 vs. RHHBY: 183.21 )
Ranked among companies with meaningful Days Inventory only.
RHHBY' s 10-Year Days Inventory Range
Min: 109.1  Med: 159.24 Max: 245.45
Current: 183.21
109.1
245.45
Days Sales Outstanding 58.75
RHHBY's Days Sales Outstanding is ranked higher than
52% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. RHHBY: 58.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
RHHBY' s 10-Year Days Sales Outstanding Range
Min: 65.9  Med: 76.03 Max: 86.72
Current: 58.75
65.9
86.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.89
RHHBY's Dividend Yield is ranked higher than
87% of the 238 Companies
in the Global Biotechnology industry.

( Industry Median: 1.25 vs. RHHBY: 2.89 )
Ranked among companies with meaningful Dividend Yield only.
RHHBY' s 10-Year Dividend Yield Range
Min: 0.74  Med: 2.79 Max: 4.55
Current: 2.89
0.74
4.55
Dividend Payout 0.74
RHHBY's Dividend Payout is ranked lower than
79% of the 118 Companies
in the Global Biotechnology industry.

( Industry Median: 0.36 vs. RHHBY: 0.74 )
Ranked among companies with meaningful Dividend Payout only.
RHHBY' s 10-Year Dividend Payout Range
Min: 0.21  Med: 0.50 Max: 0.72
Current: 0.74
0.21
0.72
Dividend growth (3y) 5.70
RHHBY's Dividend growth (3y) is ranked lower than
54% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 6.30 vs. RHHBY: 5.70 )
Ranked among companies with meaningful Dividend growth (3y) only.
RHHBY' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 11.80 Max: 27.3
Current: 5.7
0
27.3
Yield on cost (5-Year) 4.35
RHHBY's Yield on cost (5-Year) is ranked higher than
87% of the 238 Companies
in the Global Biotechnology industry.

( Industry Median: 1.49 vs. RHHBY: 4.35 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
RHHBY' s 10-Year Yield on cost (5-Year) Range
Min: 1.11  Med: 4.20 Max: 6.84
Current: 4.35
1.11
6.84
Share Buyback Rate -0.50
RHHBY's Share Buyback Rate is ranked higher than
87% of the 539 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. RHHBY: -0.50 )
Ranked among companies with meaningful Share Buyback Rate only.
RHHBY' s 10-Year Share Buyback Rate Range
Min: 78.7  Med: -0.05 Max: -0.8
Current: -0.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.68
RHHBY's Price/Projected FCF is ranked higher than
78% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. RHHBY: 1.68 )
Ranked among companies with meaningful Price/Projected FCF only.
RHHBY' s 10-Year Price/Projected FCF Range
Min: 1.27  Med: 1.72 Max: 7.13
Current: 1.68
1.27
7.13
Price/Median PS Value 1.09
RHHBY's Price/Median PS Value is ranked lower than
51% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. RHHBY: 1.09 )
Ranked among companies with meaningful Price/Median PS Value only.
RHHBY' s 10-Year Price/Median PS Value Range
Min: 0.63  Med: 1.01 Max: 1.24
Current: 1.09
0.63
1.24
Earnings Yield (Greenblatt) (%) 5.82
RHHBY's Earnings Yield (Greenblatt) (%) is ranked higher than
92% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. RHHBY: 5.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RHHBY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.1  Med: 7.10 Max: 12.7
Current: 5.82
3.1
12.7
Forward Rate of Return (Yacktman) (%) 8.80
RHHBY's Forward Rate of Return (Yacktman) (%) is ranked lower than
59% of the 100 Companies
in the Global Biotechnology industry.

( Industry Median: 13.39 vs. RHHBY: 8.80 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
RHHBY' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 2.2  Med: 11.30 Max: 79.2
Current: 8.8
2.2
79.2

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 42,621 44,124 47,364
EPS($) 12.24 13.37 14.65
EPS without NRI($) 12.24 13.37 14.65

Business Description

Industry: Biotechnology » Biotechnology
Compare:GSK, JNJ, PFE, NVS, ABT » details
Traded in other countries:RO.Switzerland, ROG.Switzerland, RHO5.Germany, RHO.Germany, ROG N.Mexico, 0QOK.UK, 0QQ6.UK, RHO6.Germany,
Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience. It has more than 66 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals and Chugai, whereas Genentech as the former third segment has been integrated into Roche Pharmaceuticals. The Diagnostics Division consists of the following four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
» More Articles for RHHBY

Headlines

Articles On GuruFocus.com
Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 
UnitedHealth Group Reports Strong Second Quarter Earnings Results Jul 21 2015 
It’s Not Too Late To Buy Gilead Sciences Jul 17 2015 
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
Roche’s Oncology Drugs Drive Its Revenue Northwards In Q1 Apr 24 2015 
Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 
What Are The Intrinsic Factors Contributing To Pfizer’s Stock Movement? Mar 27 2015 
AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
Small Cap Biotech Growth Stocks For 2015 Mar 05 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 

More From Other Websites
Roche purchases innovative nucleic acid purification technology from Lumora to enhance sample... Aug 24 2015
Roche to Buy Kapa Biosystems, Boost Diagnostics Business Aug 20 2015
Roche's (RHHBY) Lung Cancer Drug Meets Primary Endpoint Aug 17 2015
Pivotal Phase II Study Showed Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors... Aug 17 2015
AbbVie/Roche's Leukemia Drug Hits Phase II Primary Endpoint Aug 13 2015
Immune Design's Q2 Loss Narrows Y/Y, Focus on Pipeline Aug 13 2015
Breast health stock on a tear Aug 13 2015
Clovis Oncology Strikes Deal with Roche for Rociletinib Aug 12 2015
Puma Biotechnology's (PBYI) Q2 Loss Wider than Expected Aug 12 2015
Pivotal Phase II Study of Investigational Medicine Venetoclax Met Primary Endpoint in a... Aug 12 2015
Inovio Q2 Loss Wider-than-Expected, Deal with AstraZeneca - Analyst Blog Aug 11 2015
Xenon Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update Aug 10 2015
Roche Diagnostics recognizes Diagnostic Laboratory Services as Roche Molecular Center of Excellence Aug 10 2015
Pacific Biosciences Loss Wider than Expected, View Raised - Analyst Blog Aug 06 2015
3 MedTech Stocks to Buy Before Their Q2 Earnings - Earnings ESP Aug 04 2015
Regeneron Still Has Legs: Leerink Targets $630 a Share Aug 03 2015
Sea Turtle Scientist Hunts for China’s First Blockbuster Jul 30 2015
Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy Jul 30 2015
Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at... Jul 28 2015
Roche Earnings Down Y/Y, Oncology/Immunology Drive Sales - Analyst Blog Jul 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK